Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study
The DOI matches its Crossref record.
Abstract
Objective: Ketamine has been redeveloped as a rapid-acting antidepressant for treatment-resistant depression (TRD). There is a paucity of literature comparing subanesthetic intravenous (IV) ketamine and US Food and Drug Administration (FDA)–approved intranasal (IN) esketamine for TRD in real-world clinical settings. We compared the efficacy and time to achieve remission/response with repeated ketamine and esketamine. Methods: An observational study of adults with TRD received up to 6 IV ketamine (0.5 mg/kg over 40 minutes) or up to 8 IN esketamine (56- or 84-mg) treatments from August 17, 2017, to June 24, 2021. Depressive symptoms were measured utilizing the 16-item Quick Inventory of Depressive Symptomatology self-report (QIDS-SR) before and 24 hours after treatment. Cox proportional hazard models were used to evaluate associations between time to response ( ≥ 50% change in QIDS-SR score) and remission (QIDS-SR score ≤ 5). Results: Sixty-two adults (median age = 50 years, 65% female) received IV ketamine (76%, n = 47) or IN esketamine (24%, n = 15). Neither baseline-to-endpoint change in QIDS-SR score nor response/remission rates were significantly different between groups. Time to remission, defined as number of treatments (adjusting for age, body mass index , sex, and baseline QIDS-SR score), was faster for IV versus IN treatment (HR = 5.0, P = .02). Conclusions: Intravenous ketamine and intranasal esketamine showed similar rates of response and remission in TRD patients, but the number of treatments required to achieve remission was significantly lower with IV ketamine compared to IN esketamine. These findings need to be investigated in a randomized control trial comparing these two treatment interventions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study comparing intranasal esketamine with intravenous racemic ketamine (n = 62) also found no significant differences in rates of response and remission, though the number of treatments needed to achieve remission was significantly higher for intranasal esketamine [38].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [38]
Citations
Cites
Still being checked.
Cited by
Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“An observational study did not fi nd differences in ef fi cacy between intravenous R,S-ketamine and intransal Esketamine, but did suggest that R,S-ketamine acted more rapidly [46].”
BackgroundThe antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 108
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Personalized use of ketamine and esketamine for treatment-resistant depression
Medeiros, G. C., Demo, I., Goes, F. S., Zarate, C. A., & Gould, T. D. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03180-8 · Cited by 51
Hashimoto, K., Zhao, M., Zhu, T., Wang, X., & Yang, J. (2024) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2024.07.001 · Cited by 42
Calder, C. N., Kwan, A. T. H., Teopiz, K. M., Wong, S., Rosenblat, J. D., Mansur, R. B., Rhee, T. G., Ho, R., Cao, B., & McIntyre, R. S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.039 · Cited by 42
Havlik, J. L., Wahid, S., Teopiz, K. M., McIntyre, R. S., Krystal, J. H., & Rhee, T. G. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01494-4 · Cited by 36
Optimising the use of electronic medical records for large scale research in psychiatry
Newby, D., Taylor, N., Joyce, D. W., & Winchester, L. M. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02911-1 · Cited by 39
Wolfson, P., & Vaid, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1209419 · Cited by 34
Boudieu, L., Mennetrier, M., Llorca, P., & Samalin, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122773 · Cited by 32
Chrenek, C., Duong, B., Khullar, A., McRee, C., Thomas, R. K., & Swainson, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1283733 · Cited by 29
Pan, Y., Gorenflo, M. P., Davis, P. B., Kaelber, D. C., Luca, S. M. D., & Xu, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03033-4 · Cited by 25
Yrondi, A., Javelot, H., Nobile, B., Boudieu, L., Aouizerate, B., Llorca, P., Charpeaud, T., Bennabi, D., Lefrere, A., & Samalin, L. (2024) · L Encéphale · doi:10.1016/j.encep.2023.11.029 · Cited by 26
Gutiérrez, G., Swainson, J., Ravindran, N., Lam, R. W. M., Giacobbe, P., Ganapathy, K., Kowara, A., Do, A., Baskaran, A., Nestor, S. M., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116125 · Cited by 25
Núñez, N. A., Joseph, B., Kumar, R., Douka, I., Miola, A., Prokop, L. J., Mickey, B. J., & Singh, B. (2023) · Brain Sciences · doi:10.3390/brainsci13121672 · Cited by 23
Self-citationEsketamine in depression: putative biomarkers from clinical research
Johnston, J. N., Zarate, C. A., & Kvarta, M. D. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01865-1 · Cited by 24
Glynos, N. G., Aday, J. S., Kruger, D. J., Boehnke, K. F., Lake, S., & Lucas, P. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1349565 · Cited by 22
Singh, B., Voort, J. L. V., Pazdernik, V., Frye, M. A., & Kung, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.262 · Cited by 23
Self-citationSingh, B., Parikh, S. V., Voort, J. L. V., Pazdernik, V., Achtyes, E. D., Goes, F. S., Yocum, A. K., Nykamp, L. J., Becerra, A., Smart, L., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115829 · Cited by 20
Self-citationPatarroyo-Rodríguez, L., Pazdernik, V., Voort, J. L. V., Kung, S., & Singh, B. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.003 · Cited by 18
Self-citationHauser, J., Sarlon, J., Liwinski, T., Brühl, A. B., & Lang, U. E. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1327598 · Cited by 18
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 16
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis
Elmosalamy, A., Tarikogullari, I., Patarroyo-Rodríguez, L., Wilson, G., Voort, J. L. V., Kung, S., Frye, M. A., & Singh, B. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251394127 · Cited by 17
Self-citationSackeïm, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., George, M. S., McAllister-Williams, H., Prudic, J., Thase, M. E., Young, A. H., & Rush, A. J. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.046 · Cited by 17
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Price, M. Z., & Price, R. L. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100104 · Cited by 16
Joseph, B., Núñez, N. A., Kung, S., Voort, J. L. V., Pazdernik, V., Schak, K. M., Boehm, S. M., Carpenter, B., Johnson, E. K., Malyshev, G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081164 · Cited by 18
Self-citationSystematic review of parenteral ketamine for managing acute agitation in emergency settings
Peter, C., Suhas, S., Gowda, G. S., Ghadigaonkar, D. S., Muliyala, K. P., & Reddi, V. S. K. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104344 · Cited by 11
Singh, B., Pazdernik, V., Kung, S., & Voort, J. L. V. (2025) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.25m15831 · Cited by 11
Self-citationIntravenous (IV) ketamine versus intranasal esketamine for depression– Advantage IV ketamine?
Singh, B., Kung, S., & Voort, J. L. V. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.088 · Cited by 10
Self-citationGutiérrez, G., Vázquez, G. H., Ravindran, N., Lam, R. W. M., Giacobbe, P., Ganapathy, K., Kowara, A., Do, A., Baskaran, A., Nestor, S. M., et al. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986251347360 · Cited by 8
Liu, X., Liu, Y., Tu, J., Li, L., Long, T., Li, J., Deng, Y., Li, H., Peng, D., & Wu, G. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.016 · Cited by 8
Niciu, M. J., Meisner, R. C., Carr, B. R., Farooqui, A. A., Feifel, D., Kaplin, A. I., Kendrick, E., Kim, P. M., Schneck, C. D., Voort, J. L. V., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.11.008 · Cited by 8
Self-citationPatarroyo-Rodríguez, L., Pazdernik, V., Voort, J. L. V., Kung, S., Frye, M. A., & Singh, B. (2025) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.25m15941 · Cited by 7
Self-citationMathai, D. S., Cluck, M., Aslam, A. M., Amato, E., Azam, A., Banov, M., Barrett, K. A., Bonnett, C. J., Feifel, D., Grundmann, N., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121970 · Cited by 7
Le, G. H., Wong, S., Johnson, D. E., Lu, A., Orsini, D. K., Chisamore, N., Luch, S. D. D., Rosenblat, J. D., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121081 · Cited by 7
Wade, B., Pindale, R., Luccarelli, J., Li, S., Meisner, R. C., Seiner, S. J., Camprodon, J. A., & Henry, M. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01523-3 · Cited by 7
Kovacova, V., Macejova, A., Tonhajzerová, I., Višňovcová, Z., Ferencová, N., Mlyncekova, Z., Kukucka, T., Farský, I., Nosáľ, S., & Ondrejka, I. (2024) · Pharmaceuticals · doi:10.3390/ph17030358 · Cited by 7
Cavalcanti, S., Pazdernik, V., Voort, J. L. V., Kung, S., & Singh, B. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.117 · Cited by 5
Self-citationZhang, S., Afshar, H. T., Colvonen, P. J., Nokes, B. T., Compton, J. N., Mishra, J., Bismark, A. W., Ramanathan, D., & Koloski, M. F. (2025) · CNS Drugs · doi:10.1007/s40263-025-01180-w · Cited by 6
Penaluna, B. K., Voort, J. L. V., Bobo, W. V., Pazdernik, V., Achtyes, E. D., Goes, F. S., Greden, J. F., Parikh, S. V., Frye, M. A., & Singh, B. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119414 · Cited by 5
Self-citationElmaadawi, A. Z., Naha, I., Prabhudesai, S., & Eltohami, M. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116821 · Cited by 5
Chen, X., Zhou, R., Lan, L., Zhu, L., Chen, C., Zhang, X., Han, J., & Xia, L. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s463028 · Cited by 5
Balaram, K., van Dyck, L. I., Wilkins, K. M., & Maruca-Sullivan, P. E. (2023) · Current Geriatrics Reports · doi:10.1007/s13670-023-00389-1 · Cited by 7
Murata, S., Madaj, Z., Capan, C. D., Sheldon, R. D., El‐Mallakh, R. S., Parikh, S. V., Bobo, W. V., Goes, F. S., Wolkowitz, O. M., Voort, J. L. V., et al. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100503 · Cited by 7
Self-citationLandrum, R. E., Raines, A. M., Harvey, P. D., Banov, M. D., Saulnier, K. G., & Moore, M. B. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002060 · Cited by 4
Hu, H.-L., Huang, Q.-Z., & Xie, P.-X. (2026) · Medicine · doi:10.1097/md.0000000000048570 · Cited by 3
Anderson, B., & O’Grady, M. A. (2025) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-025-09975-x · Cited by 2
Sarlon, J., Liwinski, T., Brühl, A. B., Thomi, D., & Lang, U. E. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100954 · Cited by 3
Wilkinson, S. T., Prashad, S., Dalthorp, R., Harding, L., Kitay, B. M., Parikh, S. V., Dziura, J. D., Clayton, A. R., Fram, G., Lepoutre, V., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108273 · Cited by 2
Syed, O. A., Sobolenko, V., Nestor, S. M., Husain, M. I., Lipsman, N., Alam, F., & Giacobbe, P. (2026) · CNS Drugs · doi:10.1007/s40263-026-01296-7 · Cited by 2
Patarroyo-Rodríguez, L., Pazdernik, V. K., Voort, J. L. V., Kung, S., & Singh, B. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261450747 · Cited by 2
Self-citationWade, B., Pindale, R., Camprodon, J. A., Luccarelli, J., Li, S., Meisner, R. C., Seiner, S. J., & Henry, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3682009/v1 · Cited by 2
Regen, F., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_1 · Cited by 1
Patarroyo-Rodríguez, L., Voort, J. L. V., Kung, S., Brown, S. K., Cavalcanti, S., Ritter, M. J., & Singh, B. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001939 · Cited by 1
Self-citationSamalin, L., Boudieu, L., & Llorca, P. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_14 · Cited by 1
Intranasal Ketamine for Existential Distress in Advanced Cancer
Aguiar, S., Makarious, M., Lipsitz, O., deVries, F. E., Doyle, Z., McIntyre, R. S., Rodin, G., Zimmermann, C., Mak, E., Hannon, B. L., et al. (2026) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2026.04.611 · Cited by 1
Bonnet, U., Scherbaum, N., Juckel, G., & Bschor, T. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2846-4275 · Cited by 1
Evidence-Based Pharmacotherapies for Major Depressive Disorder: A Clinical Update
Marques, M. G., & Singh, B. (2026) · Psychopharmacology Bulletin · doi:10.64719/pb.18522 · Cited by 1
Self-citationRegen, F. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_1 · Cited by 1
Singh, B., MahmoudianDehkordi, S., Voort, J. L. V., Parikh, S. V., Achtyes, E. D., Goes, F. S., Bobo, W. V., Greden, J. F., Scaini, G., Tye, S. J., et al. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2724510 · Cited by 1
Self-citationSingh, B., Voort, J. L. V., & Kung, S. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_13 · Cited by 1
Self-citationKalkman, H. O., & Smigielski, L. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70019 · Cited by 1
Turkia, M. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/9yxwp · Cited by 1
Janski, A. M., Hristidis, V. C., Zorumski, C. F., & Conway, C. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00064-6
Back, M. S., Santiago, P. R. B., & Pellin, G. M. (2025) · Revista Contemporânea · doi:10.56083/rcv5n2-072
Turkia, M. (2025) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/9yxwp_v2 · Cited by 1
Chrenek, C., & Swainson, J. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_12
Future Directions of Esketamine Nasal Spray Continuation in Treatment-Resistant Depression
Price, M. Z., & Price, R. L. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_18
Zaremba, M., & Kleczkowska, P. (2025) · Neuromethods · doi:10.1007/978-1-0716-4599-4_17
Szawarnoga, D., & Sołtys, W. (2025) · Polish Annals of Medicine · doi:10.29089/paom/203684
Turkia, M. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/63su5
Psychedelic therapy in practice. Case studies of self-treatment, individual therapy & group therapy
Turkia, M. (2025) · PhilPapers (PhilPapers Foundation)
Singh, B. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002142
Self-citationBreit, S. (2026) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20260006
Singh, B., Leung, J. G., Pazdernik, V., Kung, S., & Voort, J. L. V. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002228
Self-citationWang, Y., Storaci, A. S., Alexander, G. C., & Gibbons, J. B. (2026) · Drug Safety · doi:10.1007/s40264-026-01722-1
Ketamine for Treatment-Resistant Depression
Simmons, D., Raynor, P., DuBose, D., Baliko, B., & Vick, L. (2026) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903261499294
Glynos, N. G., Aday, J. S., Kruger, D., Boehnke, K. F., Lake, S., & Lucas, P. (2024) · doi:10.3389/fpsyt.2024.1349565.s001
Metadata
- Authors
- Singh, B., Kung, S., Pazdernik, V., Schak, K. M., Geske, J., Schulte, P. J., Frye, M. A., & Voort, J. L. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2023-02-01
- Volume
- 84
- Issue
- 2
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W4318753825
- Cited by
- 66
- References
- 0
- Citations by year
- 2026: 12 · 2025: 22 · 2024: 21 · 2023: 11
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- intravenous ketamine, intranasal esketamine, treatment-resistant depression, rapid-acting antidepressants, remission, time to response, QIDS-SR, real-world effectiveness, comparative effectiveness
- MeSH terms
- Adult, Antidepressive Agents, Depression, Female, Humans, Ketamine, Male, Middle Aged, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.